{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:57:01Z","timestamp":1777859821507,"version":"3.51.4"},"reference-count":13,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>Background: Recent epidemiological data has shown a sharp increase in stimulant use among older adults, which is notable as older adults may be especially vulnerable to their cardiovascular effects. Results of recent studies have shown an increase in cardiovascular events among older adults using stimulants; however, little data exists comparing cardiovascular safety of these agents head-to-head. Objective: To determine if the incidence of serious cardiovascular events, including myocardial infarction (MI), stroke\/transient ischemic attack (TIA), or arrhythmia, are different in patients taking amphetamine\/dextroamphetamine compared with patients taking methylphenidate. Methods: Retrospective chart review of veterans 50\u00a0years and older at the Veterans Affairs North Texas Health Care System (VANTHCS) who were first prescribed a stimulant between 2015 and 2021. The primary outcome was the difference in composite cardiovascular events between amphetamine\/dextroamphetamine and methylphenidate. Secondary outcomes were the composite cardiovascular endpoints compared individually (MI, stroke\/TIA, or arrhythmia). Hazard ratios were calculated based off of a time-to-event analysis displayed using a Kaplan-Meier curve for primary and secondary outcomes. Results: 466 veterans were screened for inclusion, 30 were excluded, and 436 were included. There was no difference found in composite cardiovascular events between the 241 veterans in the amphetamine\/dextroamphetamine group and the 195 veterans in the methylphenidate group with 12 (5%) vs 8 (4.1%) events respectively ( P = .6635). There was also no difference in time-to-event analysis ( P = .4966). Conclusion: In elderly veterans, there was no difference found in incidence of major cardiovascular events with the use of amphetamine\/dextroamphetamine compared with methylphenidate.<\/jats:p>","DOI":"10.1177\/08971900241229111","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T18:40:30Z","timestamp":1705603230000},"page":"1116-1120","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiovascular Safety of Amphetamine\/Dextroamphetamine versus Methylphenidate in Older Adults"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9728-7033","authenticated-orcid":false,"given":"Rachel","family":"Paulmann","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Veterans Affairs North Texas Health Care System, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randi","family":"Stouffer","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Veterans Affairs North Texas Health Care System, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Mathys","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Veterans Affairs North Texas Health Care System, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rick","family":"Weideman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Veterans Affairs North Texas Health Care System, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Alvarez","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Texas Tech University Health Sciences Center, Lubbock, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Texas Tech University Health Sciences Center, Lubbock, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"bibr1-08971900241229111","volume-title":"Physiology, Noradrenergic Synapse","author":"Hussain LS","year":"2022"},{"key":"bibr2-08971900241229111","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2012.06.011"},{"key":"bibr3-08971900241229111","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0410-7"},{"key":"bibr4-08971900241229111","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.05.081"},{"key":"bibr5-08971900241229111","volume-title":"Drug Safety and Risk Management Advisory Committee Meeting","author":"U.S. Food and Drug Administration","year":"2006"},{"key":"bibr6-08971900241229111","unstructured":"U.S. Food and Drug Administration.\n                      FDA drug safety communication: safety review update of medications used to treat attention-deficit\/hyperactivity disorder (ADHD) in children and young adults\n                      . Food and Drug Administration 2011."},{"key":"bibr7-08971900241229111","volume-title":"Highlights of Prescribing Information: Ritalin. U.S. Food and Drug Administration","author":"Novartis Pharmaceuticals Corporation","year":"1955"},{"key":"bibr8-08971900241229111","volume-title":"Adderall: Highlights of Prescribing Information: Adderall. U.S. Food and Drug Administration","author":"Shire Pharmaceuticals","year":"2001"},{"key":"bibr9-08971900241229111","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101524"},{"key":"bibr10-08971900241229111","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000939"},{"key":"bibr11-08971900241229111","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2261-12-41"},{"key":"bibr12-08971900241229111","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.30795"},{"key":"bibr13-08971900241229111","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-3138"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900241229111","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08971900241229111","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900241229111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:38:22Z","timestamp":1777509502000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08971900241229111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1177\/08971900241229111"],"URL":"https:\/\/doi.org\/10.1177\/08971900241229111","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]}}}